Disclaimer:All content on this platform is sourced from the internet and is provided for informational purposes only. None of the content represents the views of this site, nor does it constitute investment advice. Please exercise caution when investing.
UMC rose nearly 9% in premarket trading, with revenue growth of 2.26% in 2025 marking a new second-highest level in history; biopharmaceutical company BioAge Labs continued to climb by over 14%, having closed up more than 22% on January 6.
UMC rose nearly 9% in pre-market trading, with its 2025 revenue growth of 2.26% marking a new second-highest level in history; biopharmaceutical company BioAge Labs continued to climb by over 14%, having closed up more than 22% on January 6.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice. If you find any violations, please Click to Report
Recommended Reading


